Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
Rhea-AI Summary
AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company specializing in innovative immunology therapeutics, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. Daniel Faga, the company's president and chief executive officer, will deliver a presentation on Wednesday, February 5, 2025, at 1:00 PM ET / 10:00 AM PT.
Interested parties can access a live webcast of the presentation through the investor section of the Anaptys website at http://ir.anaptysbio.com/events. The presentation recording will remain available for replay for a minimum of 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANAB declined 0.90%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch AnaptysBio's (ANAB) Guggenheim Conference presentation?
How long will the replay of ANAB's Guggenheim Conference presentation be available?
Who is presenting for AnaptysBio (ANAB) at the Guggenheim SMID Cap Biotech Conference?
